/ Portfolio /
PUSHING HEALTHCARE FORWARD
With an added value that extends far beyond capital, our portfolio companies enjoy an unprecedented access to a dedicated research and evaluation team boasting deep scientific and commercial backgrounds, as well as to the Medison’s clinical, commercial and regulatory knowledge, and to a wide network of global pharma partners. This comprehensive support helps our portfolio companies streamline development of breakthrough technologies.
Direct investments in biotech companies across development stages.
Clinical stage biotech company developing therapeutics for the treatment of muscle disorders | HQ: Lexingron, MS
Clinical stage biotech company developing novel RNA-modulating drug candidates to treat rare and ultra-rare diseases | HQ: Waltham, MA
Alpha Tau Medical
Clinical stage company, developing highly potent and conformal Alpha Radiotherapy (Alpha DaRTTM) for solid cancer tumors | HQ: Tel Aviv, Israel
Commercial stage biotech company developing novel cancer immunotherapies | HQ: Vienna, Austria
Clinical stage biotech company developing allogeneic CAR T (AlloCARTTM) therapies for cancer | HQ: SF, CA
Commercial stage biotech company developing ex-vivo autologous gene therapy to address severe and life-threatening inherited disorders | HQ: London, UK
Clinical stage biotech company developing novel small molecule drugs to extend and improve the lives of patients in areas of high unmet needs | HQ: Burlington, MA
VENTURE DEBT FUND
In 2019 Pontifax and Medison launched a $150M venture lending fund. The fund provides non-dilutive funding to innovative clinical-stage life science companies.
Pontifax is a venture capital firm investing in ground-breaking innovation in the life sciences space with $625M capital managed across 5 funds. Since 2004, Pontifax have invested in 80 private and public companies across a range of therapeutic areas and development stages.
To learn more about Pontifax:
Digital health incubator in cooperation with Amgen, Cleveland Clinic, Macabbi Healthcare Services and Shanghai Creation Investment Fund.
LinkEdge is an investment vehicle, supporting innovative projects from top academic institutions and medical centers.